R G Langley

Summary

Affiliation: Dalhousie University
Country: Canada

Publications

  1. doi request reprint Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis
    R G Langley
    Queen Elizabeth II Health Sciences Centre, Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS B3H 2Y9, Canada
    Br J Dermatol 162:1349-58. 2010
  2. doi request reprint Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    R G Langley
    Queen Elizabeth II Health Sciences Centre, Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Canada
    J Eur Acad Dermatol Venereol 26:21-9. 2012
  3. doi request reprint Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus
    R G Langley
    Dalhousie University, Halifax, NS, Canada
    J Eur Acad Dermatol Venereol 26:373-81. 2012
  4. ncbi request reprint Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches
    Richard G Langley
    Queen Elizabeth II Health Science Centre, Dalhousie University, 4195 Dickson Building, B3H 2Y9, Halifax, NS
    J Cutan Med Surg 9:18-25. 2006
  5. ncbi request reprint In vivo confocal scanning laser microscopy of benign lentigines: comparison to conventional histology and in vivo characteristics of lentigo maligna
    Richard G B Langley
    QEII Health Sciences Centre, Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
    J Am Acad Dermatol 55:88-97. 2006
  6. ncbi request reprint Duration of remission of biologic agents for chronic plaque psoriasis
    Richard G Langley
    Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
    J Drugs Dermatol 6:1205-12. 2007
  7. ncbi request reprint Confocal scanning laser microscopy of benign and malignant melanocytic skin lesions in vivo
    R G Langley
    Department of Dermatology and Dermatopathology Unit, Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Am Acad Dermatol 45:365-76. 2001
  8. doi request reprint An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance
    Richard G B Langley
    Division of Dermatology, Department of Medicine, Dalhousie University, and Queen Elizabeth II Health Science Centre, Halifax, NS, Canada
    Dermatology 215:27-44. 2007
  9. ncbi request reprint The diagnostic accuracy of in vivo confocal scanning laser microscopy compared to dermoscopy of benign and malignant melanocytic lesions: a prospective study
    Richard G B Langley
    Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS, Canada
    Dermatology 215:365-72. 2007
  10. ncbi request reprint Biologic therapeutics in the treatment of psoriasis. Part 1: review
    Richard G Langley
    Department of Medicine, Dalhousie University, Halifax, NS, Canada
    J Cutan Med Surg 11:99-122. 2007

Detail Information

Publications35

  1. doi request reprint Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis
    R G Langley
    Queen Elizabeth II Health Sciences Centre, Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS B3H 2Y9, Canada
    Br J Dermatol 162:1349-58. 2010
    ..Safety of tumour necrosis factor (TNF) antagonists is a primary concern for clinicians prescribing them to patients with psoriasis...
  2. doi request reprint Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    R G Langley
    Queen Elizabeth II Health Sciences Centre, Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Canada
    J Eur Acad Dermatol Venereol 26:21-9. 2012
    ..The benefit-risk profiles generated demonstrated that, during the initial year of treatment, likelihood of success with TNF-α antagonists was several orders of magnitude greater than the likelihood of serious toxicity...
  3. doi request reprint Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus
    R G Langley
    Dalhousie University, Halifax, NS, Canada
    J Eur Acad Dermatol Venereol 26:373-81. 2012
    ..Clinical data and guidelines for managing and treating psoriasis patients with both skin and nail symptoms are limited...
  4. ncbi request reprint Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches
    Richard G Langley
    Queen Elizabeth II Health Science Centre, Dalhousie University, 4195 Dickson Building, B3H 2Y9, Halifax, NS
    J Cutan Med Surg 9:18-25. 2006
    ....
  5. ncbi request reprint In vivo confocal scanning laser microscopy of benign lentigines: comparison to conventional histology and in vivo characteristics of lentigo maligna
    Richard G B Langley
    QEII Health Sciences Centre, Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
    J Am Acad Dermatol 55:88-97. 2006
    ..Physician diagnostic accuracy is less than perfect, prompting research into noninvasive technology such as reflectance mode in vivo confocal scanning laser microscopy (CSLM)...
  6. ncbi request reprint Duration of remission of biologic agents for chronic plaque psoriasis
    Richard G Langley
    Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
    J Drugs Dermatol 6:1205-12. 2007
    ..Another important endpoint is remission, or duration of response off therapy, which reduces exposure to immunosuppressive agents and potentially lowers costs...
  7. ncbi request reprint Confocal scanning laser microscopy of benign and malignant melanocytic skin lesions in vivo
    R G Langley
    Department of Dermatology and Dermatopathology Unit, Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Am Acad Dermatol 45:365-76. 2001
    ..The ability of physicians for early diagnosis of cutaneous melanomas is less than perfect, prompting research into noninvasive methods for diagnosis...
  8. doi request reprint An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance
    Richard G B Langley
    Division of Dermatology, Department of Medicine, Dalhousie University, and Queen Elizabeth II Health Science Centre, Halifax, NS, Canada
    Dermatology 215:27-44. 2007
    ..While cases of malignancy have been reported in patients who have used pimecrolimus cream 1%, there is no clinical evidence to establish that treatment with pimecrolimus cream 1% increases the risk of malignancy...
  9. ncbi request reprint The diagnostic accuracy of in vivo confocal scanning laser microscopy compared to dermoscopy of benign and malignant melanocytic lesions: a prospective study
    Richard G B Langley
    Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS, Canada
    Dermatology 215:365-72. 2007
    ..The aim of this study was to evaluate the diagnostic accuracy of CSLM compared to dermoscopy in a prospective examination of benign and malignant melanocytic lesions...
  10. ncbi request reprint Biologic therapeutics in the treatment of psoriasis. Part 1: review
    Richard G Langley
    Department of Medicine, Dalhousie University, Halifax, NS, Canada
    J Cutan Med Surg 11:99-122. 2007
    ....
  11. ncbi request reprint Temporary tattoos to simulate skin disease: report and validation of a novel teaching tool
    Richard G B Langley
    Department of Medicine, Division of Dermatology, Dalhousie University, Halifax, Nova Scotia, Canada
    Acad Med 84:950-3. 2009
    ..The authors carried out this study to learn whether a novel educational tool, a temporary tattoo, could successfully simulate an MM...
  12. doi request reprint Treatment and management of psoriasis with nail involvement: a focus on biologic therapy
    Richard G Langley
    Queen Elizabeth II Health Sciences Centre, Dalhousie University, 1278 University Avenue, Halifax, Nova Scotia, Canada
    Dermatology 221:29-42. 2010
    ..The extra disease burden that nail symptoms place on the patient can be considered indicative of a more severe form of the disease and should be taken into consideration when assessing treatment options...
  13. ncbi request reprint Biologic therapeutics in the treatment of psoriasis. Part 2: practical considerations
    Richard G Langley
    Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS
    J Cutan Med Surg 11:145-9. 2007
    ....
  14. ncbi request reprint Alefacept: an expert review concerning the treatment of psoriasis
    Richard G Langley
    Dalhousie University, Center for Clinical Research, 5820 University Avenue, Halifax, NS, B3H 1V7, Canada
    Expert Opin Pharmacother 6:2327-33. 2005
    ..In addition, data are reviewed on the use of alefacept in combination with other agents and in other diseases, including psoriatic arthritis...
  15. ncbi request reprint Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience
    Richard G B Langley
    Dalhousie University, Halifax, Nova Scotia, Canada
    Clin Ther 27:1317-28. 2005
    ..Efalizumab is a biologic therapy targeted to inhibit T cells. Its efficacy has been shown in clinical trials encompassing >3500 patients with psoriasis...
  16. pmc A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
    A B Gottlieb
    Tufts Medical Center, Boston, MA, USA
    Br J Dermatol 167:649-57. 2012
    ..Etanercept plus methotrexate combination therapy has not been adequately investigated in psoriasis...
  17. doi request reprint Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
    K Reich
    Dermatologikum Hamburg, Hamburg, Germany Dalhousie University, Halifax, NS, Canada
    Br J Dermatol 164:862-72. 2011
    ..Patients with psoriasis are believed to be at an increased risk of cardiovascular (CV) morbidity, and the effect of biological agents on CV safety is not fully understood...
  18. ncbi request reprint Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis
    R G Langley
    Dalhousie University, Halifax, NS, Canada Probity Medical Research, Waterloo, ON, Canada Tufts Medical Centre, Boston, MA, USA University of Utah Health Sciences Centre, Salt Lake City, UT, USA Northwestern University, Evanston, IL, USA Abbott Laboratories, Abbott Park, IL, USA University of Connecticut School of Medicine, Farmington, CT, USA
    J Eur Acad Dermatol Venereol 27:1252-61. 2013
    ..Anti-interleukin-12/23 treatment (anti-IL-12/23) has recently demonstrated significant efficacy for moderate to severe psoriasis, yet potential safety signals warrant further investigation...
  19. doi request reprint Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis
    Richard G B Langley
    Dalhousie University and Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada
    Pediatr Dermatol 25:301-7. 2008
    ..The incidence of adverse events was low and comparable between treatment groups. In conclusion, pimecrolimus cream 1% is effective and well tolerated in the long-term control of children with mild to moderately severe atopic dermatitis...
  20. ncbi request reprint Prognostic significance of vascularity in cutaneous melanoma: pilot study using in vivo confocal scanning laser microscopy
    Shannon Humphrey
    Division of Anatomical Pathology, Department of Medicine, Dalhousie University, Halifax, NS
    J Cutan Med Surg 10:122-7. 2006
    ..Tumor vascularity may be of strong prognostic significance in cutaneous melanoma. We are the first to use a novel, noninvasive, in vivo confocal scanning laser microscope (CSLM) to evaluate vascularity in cutaneous melanoma...
  21. ncbi request reprint Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis
    Donald V Belsito
    Division of Dermatology, University of Kansas Medical Center, 4023 Wescoe Pavillion, Kansas City, KS 66160, USA
    Cutis 73:31-8. 2004
    ..Pimecrolimus was well tolerated, with a low rate of application-site reactions such as burning. Pimecrolimus cream 1%, when used twice daily with overnight occlusion, may be of benefit in the management of chronic HD...
  22. doi request reprint The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials
    R G Langley
    Queen Elizabeth II Health Sciences Centre, Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS, B3H 2Y9, Canada
    Br J Dermatol 169:1198-206. 2013
    ..Understanding differences in trial design and data handling is essential to make informed treatment decisions...
  23. doi request reprint Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
    K A Papp
    Probity Medical Research, 135 Union Street East, Waterloo, ON N2J 1C4, Canada
    Br J Dermatol 167:668-77. 2012
    ..Tofacitinib is a novel, oral Janus kinase inhibitor under investigation as a potential treatment for plaque psoriasis...
  24. ncbi request reprint Famciclovir for the treatment of recurrent genital and labial herpes lesions
    R G Langley
    Division of Dermatology, Department of Medicine, and Centre for Clinical Research, Dalhousie University, Halifax, NS, Canada
    Skin Therapy Lett 10:5-7. 2005
    ..For the treatment of labial herpes, a single 1,500 mg dose of famciclovir shortened the lesion healing time, shortened the time to normal skin, and resulted in faster resolution of pain and tenderness...
  25. ncbi request reprint Reflectance-mode confocal microscopy for the diagnosis of sebaceous hyperplasia in vivo
    Iva Propperova
    Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia
    Arch Dermatol 143:134. 2007
  26. ncbi request reprint Erdheim-Chester disease of the breast: a case report and review of the literature
    Penny J Barnes
    Division of Anatomical Pathology, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada
    Breast J 11:462-7. 2005
    ..ECD should be considered in the differential diagnosis of histiocytoid breast lesions, including fat necrosis and histiocytoid invasive mammary carcinoma...
  27. ncbi request reprint In vivo confocal imaging of pigmented eccrine poroma
    Rieko Tachihara
    Wellman Laboratories of Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, USA
    Dermatology 204:185-9. 2002
    ..Near-infrared reflectance confocal microscopy (CM) imaging is a noninvasive technique that can be utilized to evaluate histologic features of cutaneous lesions in vivo...
  28. ncbi request reprint Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice
    Jann Lubbe
    Clinique et Policlinique de Dermatologie et Vénéréologie, Hopital Cantonal Universitaire, Geneva, Switzerland
    Am J Clin Dermatol 7:121-31. 2006
    ..The objective of this study was to evaluate the safety and efficacy of a pimecrolimus-based regimen in daily practice...
  29. ncbi request reprint Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents
    Lawrence F Eichenfield
    Pediatric and Adolescent Dermatology, Children s Hospital San Diego, 3020 Children s Way, Mail Code 5092, San Diego, CA 92123, USA
    J Am Acad Dermatol 46:495-504. 2002
    ..The ascomycin derivative pimecrolimus (ASM 981) is a cell-selective cytokine inhibitor, specifically developed for the treatment of inflammatory skin diseases...
  30. ncbi request reprint Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial
    Wolfram Sterry
    Psoriasis Study Center, Department of Dermatology and Allergy, University Hospital Charite, Berlin, Germany
    J Dtsch Dermatol Ges 4:947-56. 2006
    ..Time to relapse after treatment cessation, and efficacy/safety of 12 weeks' open-label re-treatment in patients achieving PASI-75 at week 12 FT were also assessed...
  31. ncbi request reprint 1% pimecrolimus cream for atopic dermatitis
    Lawrence F Eichenfield
    Arch Dermatol 139:1369-70; author reply 1370-1. 2003
  32. ncbi request reprint Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence
    Michael Iskedjian
    PharmIdeas Research and Consulting Inc, Oakville, Ontario, Canada
    Am J Clin Dermatol 5:267-79. 2004
    ..To summarize success rates of the topical calcineurin inhibitors tacrolimus and pimecrolimus in treating atopic dermatitis...
  33. ncbi request reprint A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis
    Craig L Leonardi
    St Louis University School of Medicine, St Louis, MO 63117, USA
    Dermatology 213:204-14. 2006
    ..Efalizumab is a recombinant monoclonal immunoglobulin G1 (IgG1) antibody approved for use in psoriasis patients...
  34. ncbi request reprint Mycosis fungoides presenting as pigmented purpuric dermatitis
    Shannon Hanna
    Department of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada
    Pediatr Dermatol 23:350-4. 2006
    ..In our patient, histologic features were typical of Mycosis fungoides presenting as pigmented purpuric dermatitis. The clinical features, pathology, molecular biology, and the relationship between these two entities are discussed...
  35. ncbi request reprint Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome
    Lawrence F Eichenfield
    Children s Hospital, San Diego, CA, USA
    Int J Dermatol 44:70-5. 2005
    ..This report examines the effect of ethnic origin and baseline disease severity on treatment outcomes in pediatric patients with AD treated with pimecrolimus cream 1%...